ALK and non-small cell lung carcinoma: In a study of 39 ALK-rearranged NSCLC patients treated with crizotinib, Pailler et al. found aberrant ALK copy number gain in CTCs and correlated the dynamic changes in the levels of these CTCs with PFS.